Read more about the current advancements and innovations made towards finding a cure for ALS (Lou Gehrig’s disease)
WIRED talks to Jackie Hunter about the positive disruption BenevolentAI is bringing to the pharma industry, and the scientific unknowns its helping to unlock using AI.
FierceBiotech covers the news that we have hired Dr Ian Churcher MA, DPhil as VP of Drug Discovery and Preclinical development. Ian joins from GSK where he previously headed up a Discovery Performance Unit.
BenevolentAI, one of the world’s largest private AI companies, today announced it has hired Dr Ian Churcher as its new VP of Drug Discovery & Preclinical Development of its bioscience subsidiary BenevolentBio.
Our recent work with the Sheffield Institute of Translational Neuroscience (SITraN) on finding treatments for ALS is featured on Reuters UK. BenevolentBio CEO Professor Jackie Hunter and Dr Richard Mead of SITraN are interviewed about the effects of the disease and the process involved in finding the treatments.
Lynsey Barber reports on BenevolentAI office opening in New York
BenevolentAI, one of the world’s largest private AI companies, today announced it is expanding its footprint in the United States by opening an office in New York City and has made two significant hires - Keith Hall, from Google, and Daniel Neil, from the Institute of Neuroinformatics, that will form the foundation of the new New York BenevolentAI team.
Professor Jackie Hunter speaks to the Science Disrupt podcast about the potential to improve the drug discovery process with machine learning, as well as how AI is streamlining science more generally. In addition to opening up the potential for a whole new universe of potential findings, the podcast covers what this means for science as an evidence-based endeavour and whether it can help to reduce publication bias.
One of the world’s largest private AI companies – BenevolentAI, that develops and applies artificial intelligence for scientific innovation, today announced it has hired Dr Nathan Brown BSc (Hons) FRSC, as its new Head of Cheminformatics following the promotion of Mark Davies from Head of Cheminformatics at BenevolentAI to VP Biomedical Informatics earlier in the year.
Taking a closer look at how big data and machine learning is transforming precision medicine, Adi Gaskell covers our work at BenevolentAI and the partnership with Sheffield Institute for Translational Neuroscience (SITraN) for Motor Neuron Disease research.
We teamed up with Sheffield Institute for Translational Neuroscience (SITraN) to test some of our AI-driven hypotheses in its ALS disease models. Dr Laura Ferraiulo, co-lead on the project from SITraN, spoke to IDG Connect about how this led to a potentially major breakthrough.
Our founder Ken Mulvany features in an article looking at the UK’s growing performance in AI technology and the investment the country’s industry is attracting. Ken speaks to Bloomberg’s Giles Turner about BenevolentAI's hiring spree and the 50 roles we are looking to fill.
Sheffield and London, UK - 25 May 2017. The Sheffield Institute for Translational Neuroscience (SITraN), part of the University of Sheffield and one of the world’s leading centres for research into Motor Neurone Disease, Alzheimer’s and Parkinson’s Disease, today announced that its research into a drug candidate discovered by British artificial intelligence firm BenevolentAI has delivered positive results.
Nanalyze includes BenevolentAI in its round up of computational drug discovery start-ups using AI.
Ken Mulvany, is interviewed by Business Insider UK in an article exploring BenevolentAI’s work to develop new drugs for diseases like Alzheimer’s and ALS.
This week, Pharmaphorum covered our partnership announcement with MRC Technology. We’ve teamed up with the independent research charity to investigate new small molecule and antibody drug candidates, combining our technology and R&D experience with their expertise.
London, 11 April 2017 – BenevolentAI, a British artificial intelligence company, today announced that it has partnered with MRC Technology (“MRCT”), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
An interview with Jackie Hunter, CEO BenevolentBio, the drug discovery arm of BenevolentAI
Read more about TechCrunch's article on startups using artificial intelligence and machine learning to improve healthcare.
The article discusses the rapid transformation of medical research lead by data, artificial intelligence and supercomputers
The Financial Times takes a look at the work we’re doing at BenevolentAI to “revolutionise medical research” after speaking to Co-Founder and Director, Ken Mulvany.
By Adi Gaskell
By Tech City News